Clinical trials: First Line Treatment
Advanced Pancreatic Cancer
Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients
The present study is intended to investigate the efficacy and safety of the patients with confirmed advanced pancreatic cancer after treating with the combination of paclitaxel liposome plus S-1.
- Trial name
- NCT04217096
- Testing
- Paclitaxel liposome, S-1
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
PTSD - Post Traumatic Stress Disorder
First-Line Intervention for PTSD - Intensive Treatment
The goal of this clinical trial is to learn if an intensive program can treat post-traumatic stress disorder (PTSD) in adults getting treatment for the first time, and whether it has lower societal costs.
- Trial name
- FLIP-IT (NCT06700590)
- Testing
- Intensive Treatment, Treatment as usual
- Where
- 4 sites in Netherlands
- Volunteers
- 186 people
- Sponsor
- ARQ National Psychotrauma Centre
Lung Cancer
First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer
Phase II, single-arm study to assess the safety and efficacy of osimertinib (80 mg, orally, once daily) as first-line therapy in patients with EGFR mutation-positive, locally advanced or metastatic non-small cell lung cancer…
- Trial name
- FIOL (NCT03804580)
- Testing
- osimertinib
- Where
- 10 sites in Denmark, Lithuania and 2 more
- Volunteers
- 100 people
- Sponsor
- Vestre Viken Hospital Trust
Breast Neoplasms
Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer
This is an international, multicentre, double-blind, controlled, randomized phase II study comparing the efficacy and safety of fulvestrant in combination with palbociclib versus fulvestrant plus placebo in postmenopausal women…
- Trial name
- FLIPPER (NCT02690480)
- Testing
- PD-0332991 (Palbociclib), Fulvestrant
- Where
- 32 sites in Ireland, Spain
- Volunteers
- 189 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer
Personalised Disease Monitoring in Metastatic Breast Cancer
Patients with metastatic breast cancer may respond well to treatment and metastases can remain stable for several years. Despite personalised medicine being increasingly used for diagnosis and treatment, follow-up still include…
- Trial name
- PDM-MBC (NCT04597580)
- Where
- 7 sites in Sweden, United Kingdom
- Volunteers
- 97 people
- Sponsor
- The Christie NHS Foundation Trust
Crohn's Disease
A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will evaluate the second line effectiveness of upadacitinib and risankizumab in Crohn's Disease (CD) in a real-world…
- Trial name
- CROHNOS (NCT07073079)
- Where
- 25 sites in Italy
- Volunteers
- 250 people
- Sponsor
- AbbVie
PDAC - Pancreatic Ductal Adenocarcinoma
Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients
The purpose of this study is to determine the efficacy of sitagliptin combined with gemcitabine and albumin-bound paclitaxel in subjects with locally advanced and metastatic pancreatic ductal adenocarcinoma.
- Trial name
- NCT05947825
- Testing
- Combination of sitagliptin+ gemcitabine + nab-paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Aspergillosis, Invasive Pulmonary Aspergillosis
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
This study aims to compare the safety, tolerability, and efficacy of voriconazole and anidulafungin in combination versus voriconazole alone in pediatric subjects aged 2 to 17 years with invasive aspergillosis.
- Conditions
- Aspergillosis, Invasive Pulmonary Aspergillosis, Neuroaspergillosis
- Trial name
- NCT01188759
- Testing
- Voriconazole, Anidulafungin
- Sponsor
- Pfizer
Metastatic Breast Cancer
Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC
Primary objective of this study is to evaluate the efficacy of gemcitabine and cisplatin as first line therapy in patients with triple-negative MBC. 80 patients will be treated into this study.
- Trial name
- NCT00601159
- Testing
- gemcitabine and cisplatin
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Fudan University
Pancreatic Cancer
Chemotherapy Compared to Biological Therapy in Treating Patients With Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00003780
- Testing
- tumor infiltrating lymphocyte therapy, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Meyer Pharmaceuticals
Acute Lymphoblastic Leukemia, Adult
RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL
This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of adolescent and young patients with ph-negative acute lymphoblastic leukemia with first-line…
- Trial name
- NCT05127148
- Testing
- Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.
- Where
- 2 sites in Argentina
- Volunteers
- 100 people
- Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda
Breast Cancer
Combination Chemotherapy for Metastatic Breast Cancer
The purpose of this study is to determine the objective tumor response of the first-line therapy combination of gemcitabine and cisplatin in patients with metastatic breast cancer
- Trial name
- NCT00191815
- Testing
- Gemcitabine, cisplatin
- Where
- 2 sites in Germany, Russia
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer
Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)
The aim of this study is to explore the efficacy and safety of a new combination regimen of GnP regimen, SBRT and the anti-PD-1/VEGF bis-antibody, Ivonescimab, in patients with recurrent metastatic advanced pancreatic cancer.
- Trial name
- NCT06991491
- Testing
- GnP in combination with Ivonescimab and SBRT
- Volunteers
- 29 people
- Sponsor
- West China Hospital
Helicobacter Pylori Infection
Efficacy and Safety of Bismuth Quadruple Therapy Containing Cefuroxime and Tetracycline as First-line Therapy for Eradicating Helicobacter Pylori in Patients Allergic to Penicillin
The researchers collected untreated H. pylori positive patients from outpatient clinics. Subjects were randomly assigned to receive either 14 days of bismuth quadruple therapy with cefuroxime and tetracycline or 14 days of…
- Trial name
- NCT06351891
- Testing
- 14-day bismuth quadruple regimen containing cefuroxime and tetracycline, 14-day bismuth quadruple regimen containing cefuroxime and levofloxacin
- Where
- China
- Volunteers
- 248 people
- Sponsor
- Qilu Hospital of Shandong University
Endometrial Cancer, Fallopian Tube Cancer
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00004082
- Testing
- carboplatin, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
Clear-cell Renal Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma
Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
Disease and Stage: Metastatic and locally advanced clear cell renal carcinoma An open-label, exploratory, single-arm, multicenter trial.
- Trial name
- NEORAD (NCT01715935)
- Testing
- Everolimus
- Where
- 10 sites in France
- Volunteers
- 25 people
- Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Pancreatic Cancer
Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer
This is a single-arm, prospective, multicenter, open-label clinical trial, which aims to observe and evaluate the efficacy and safety of Relafen-α combined with famitinib and AG chemotherapy as first-line therapy in patients with…
- Trial name
- NCT07814859
- Testing
- Retlirafusp alfa Injection, Famitinib, AG
- Where
- China
- Volunteers
- 88 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Triple Negative Metastatic Breast Cancer
Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemotherapy).
- Trial name
- NCT01069796
- Testing
- Paclitaxel, Bevacizumab, Capecitabine
- Where
- 17 sites in France
- Volunteers
- 64 people
- Sponsor
- ARCAGY/ GINECO GROUP
Non-small Cell Lung Cancer
Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
This is an open-label, multicenter, Phase 1 clinical study to evaluate the bioavailability of tislelizumab subcutaneous (SC) injection in the first-line treatment of participants with advanced or metastatic non-small cell lung…
- Trial name
- NCT06091943
- Testing
- Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet
- Where
- 15 sites in China, Georgia and 1 more
- Volunteers
- 62 people
- Sponsor
- BeiGene
HER2-positive Gastric Cancer
RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
A single-arm, single-center phase II trial study to assess the efficacy and safety of disitamab vedotin plus cadonilimab as first-line therapy for HER2-overexpressing advanced stomach carcinoma
- Trial name
- NCT06492317
- Testing
- Disitamab Vedotin, Cadonilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.